Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654377 | 0.85 | TSHR (0.47) | TSHR | |
| SCHEMBL7365796 | 0.69 | — | — | |
| SCHEMBL4452909 | 0.69 | — | — | |
| SCHEMBL11677128 | 0.67 | TSHR (0.37) | TSHR | |
| SCHEMBL269836 | 0.67 | — | — | |
| SCHEMBL12388848 | 0.67 | — | — | |
| SCHEMBL904822 | 0.67 | — | — | |
| SCHEMBL18935094 | 0.67 | — | — | |
| SCHEMBL888827 | 0.67 | — | — | |
| SCHEMBL9793411 | 0.67 | TSHR (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390627-B2 | Process for improved opioid synthesis | RHODES TECHNOLOGIES (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3525788-B1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE (DE) | 2022-05-25 | — | — | EP | disclosed |
| EP-2852404-B1 | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2654751-B1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA LP (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-1986598-A1 | UV FILTER CAPSULES COMPRISING AN AMINOSUBSTITUTED HYDROXYBENZOPHENONE | Merck Patent GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1556354-B1 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007093252-A1 | UV FILTER CAPSULES COMPRISING AN AMINOSUBSTITUTED HYDROXYBENZOPHENONE | MERCK PATENT GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390627-B2 | Process for improved opioid synthesis | OPRK1, OPRM1, OPRD1 | TSHR 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.